BioSpace News Archive

Policy

Ambitious Bluebird Seeks Three Drug Approvals by 2019

As yet, the company has no products on the market, so the applications, if approved, would mark the company’s shift into a commercial company.

January 10, 2018
·
3 min read
·
Mark Terry
Policy

Forensic Exam Shows Pattern in 4 Deaths of Sanofi Dengue Vaccine Recipients

Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine.

January 10, 2018
·
1 min read
FDA

PTC Therapeutics CEO to Fight for DMD Therapy, Pushes Forward with SMA Treatment

The company believes the Translarna data is compelling and pointed to the success the drug is having in Europe.

January 10, 2018
·
3 min read
·
Alex Keown
Genmab: Major Shareholder Announcement - Jan. 10, 2018

As of January 5, 2018, Artisan Partners Limited Partnership has increased their indirect ownership in Genmab A/S to 3,081,731 shares.

January 10, 2018
·
3 min read
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2017

Essilor International is the world’s leading ophthalmic optics company.

January 10, 2018
·
1 min read
Drug Development

First Treatment for SAb Biotherapeutics’ MERS Drug Appears Safe in NIH Phase I Clinical Trial

Results of the study were published today in The Lancet Infectious Diseases.

January 10, 2018
·
4 min read
Pharm Country

New Jersey’s Braeburn Pharma Lands $110M

Proceeds to finance investigational buprenorphine weekly and monthly depot injection for the treatment of adults with opioid use disorder.

January 10, 2018
·
4 min read
Policy

BIO Statement on House Energy & Commerce Committee 340B Drug Pricing Program Review

BIO President and CEO Jim Greenwood issued the following statement regarding the review of the 340B drug pricing program released by the House Energy & Commerce Committee today:

January 10, 2018
·
2 min read
Pharm Country

Misonix to Ring Nasdaq Closing Bell on January 10

The ceremony is being held to celebrate the Company’s 25 years of listing on the Nasdaq.

January 10, 2018
·
2 min read
Biotech Bay

CureVac Highlights Key 2018 Corporate Milestones and Outlook

CureVac AG today outlined key 2018 milestones in conjunction with its presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.

January 10, 2018
·
5 min read